NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55111-0137-81 | 55111-0137 | Isotretinoin | ZENATANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Mar 26, 2013 | In Use | |
64380-0159-01 | 64380-0159 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Apr 4, 2022 | In Use | ||
13668-0591-82 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct 21, 2020 | In Use | |
10631-0118-31 | 10631-0118 | Isotretinoin | Absorica | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 8, 2012 | In Use | |
00555-0607-04 | 00555-0607 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Nov 30, 1995 | Dec 31, 2015 | In Use | |
00615-3570-39 | 00615-3570 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug 8, 1988 | In Use | ||
60429-0433-05 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sep 4, 2015 | Mar 31, 2024 | No Longer Used | |
63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | Mar 31, 2025 | No Longer Used |
00781-2321-51 | 00781-2321 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
00006-5331-01 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | Aug 13, 2021 | In Use | |
54868-1629-00 | 54868-1629 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Jul 5, 2007 | In Use | ||
00378-6614-85 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 11, 2015 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
68001-0655-17 | 68001-0655 | ISOTRETINOIN | ZENATANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 11, 2025 | In Use | |
00143-9136-01 | 00143-9136 | Mitomycin | Mitomycin | 40.0 mg/1 | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct 1, 2022 | In Use | |
42388-0025-37 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb 27, 2019 | In Use | |
00555-1057-56 | 00555-1057 | Isotretinoin | Claravis | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 9, 2003 | In Use | |
00904-7236-61 | 00904-7236 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Jun 1, 2022 | In Use | ||
59651-0636-03 | 59651-0636 | ISOTRETINOIN | ISOTRETINOIN | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan 29, 2024 | In Use | |
72143-0254-30 | 72143-0254 | ISOTRETINOIN | ACCUTANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Aug 1, 2022 | In Use | |
55154-0885-03 | 55154-0885 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Nov 30, 1995 | Jan 13, 2015 | No Longer Used | |
52125-0515-01 | 52125-0515 | Methylprednisolone Sodium Succinate | Solu-Medrol | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intravenous | Feb 13, 2013 | Feb 13, 2014 | No Longer Used |
57664-0025-97 | 57664-0025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec 29, 2020 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | Mar 31, 2025 | No Longer Used |
00469-1725-56 | 00469-1725 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use |
Found 11765 results — Export these results